vs

Side-by-side financial comparison of EDGEWELL PERSONAL CARE Co (EPC) and Orthofix Medical Inc. (OFIX). Click either name above to swap in a different company.

EDGEWELL PERSONAL CARE Co is the larger business by last-quarter revenue ($422.8M vs $219.9M, roughly 1.9× Orthofix Medical Inc.). Orthofix Medical Inc. runs the higher net margin — -1.0% vs -15.5%, a 14.5% gap on every dollar of revenue. On growth, Orthofix Medical Inc. posted the faster year-over-year revenue change (2.0% vs -11.6%). Orthofix Medical Inc. produced more free cash flow last quarter ($16.8M vs $-137.5M). Over the past eight quarters, Orthofix Medical Inc.'s revenue compounded faster (8.0% CAGR vs -16.0%).

The Edgewell Personal Care Company is an American multinational consumer products company headquartered in Shelton, Connecticut. It was formed in 2015 following the corporate spin-off from Energizer Holdings, Inc..

Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.

EPC vs OFIX — Head-to-Head

Bigger by revenue
EPC
EPC
1.9× larger
EPC
$422.8M
$219.9M
OFIX
Growing faster (revenue YoY)
OFIX
OFIX
+13.6% gap
OFIX
2.0%
-11.6%
EPC
Higher net margin
OFIX
OFIX
14.5% more per $
OFIX
-1.0%
-15.5%
EPC
More free cash flow
OFIX
OFIX
$154.3M more FCF
OFIX
$16.8M
$-137.5M
EPC
Faster 2-yr revenue CAGR
OFIX
OFIX
Annualised
OFIX
8.0%
-16.0%
EPC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
EPC
EPC
OFIX
OFIX
Revenue
$422.8M
$219.9M
Net Profit
$-65.7M
$-2.2M
Gross Margin
38.1%
71.1%
Operating Margin
-4.5%
0.2%
Net Margin
-15.5%
-1.0%
Revenue YoY
-11.6%
2.0%
Net Profit YoY
-3028.6%
92.4%
EPS (diluted)
$-1.41
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EPC
EPC
OFIX
OFIX
Q4 25
$422.8M
$219.9M
Q3 25
$600.5M
$205.6M
Q2 25
$627.2M
$203.1M
Q1 25
$580.7M
$193.6M
Q4 24
$415.1M
$215.7M
Q3 24
$517.6M
$196.6M
Q2 24
$647.8M
$198.6M
Q1 24
$599.4M
$188.6M
Net Profit
EPC
EPC
OFIX
OFIX
Q4 25
$-65.7M
$-2.2M
Q3 25
$-30.6M
$-22.8M
Q2 25
$29.1M
$-14.1M
Q1 25
$29.0M
$-53.1M
Q4 24
$-2.1M
$-29.1M
Q3 24
$8.8M
$-27.4M
Q2 24
$49.0M
$-33.4M
Q1 24
$36.0M
$-36.0M
Gross Margin
EPC
EPC
OFIX
OFIX
Q4 25
38.1%
71.1%
Q3 25
37.9%
72.2%
Q2 25
42.8%
68.7%
Q1 25
44.1%
62.8%
Q4 24
41.6%
69.0%
Q3 24
41.1%
68.7%
Q2 24
44.3%
67.8%
Q1 24
43.1%
67.5%
Operating Margin
EPC
EPC
OFIX
OFIX
Q4 25
-4.5%
0.2%
Q3 25
-4.2%
-8.3%
Q2 25
8.6%
-7.9%
Q1 25
10.1%
-25.2%
Q4 24
2.2%
-5.3%
Q3 24
3.9%
-9.6%
Q2 24
12.8%
-12.5%
Q1 24
11.7%
-15.6%
Net Margin
EPC
EPC
OFIX
OFIX
Q4 25
-15.5%
-1.0%
Q3 25
-5.1%
-11.1%
Q2 25
4.6%
-6.9%
Q1 25
5.0%
-27.4%
Q4 24
-0.5%
-13.5%
Q3 24
1.7%
-13.9%
Q2 24
7.6%
-16.8%
Q1 24
6.0%
-19.1%
EPS (diluted)
EPC
EPC
OFIX
OFIX
Q4 25
$-1.41
$-0.05
Q3 25
$-0.65
$-0.57
Q2 25
$0.62
$-0.36
Q1 25
$0.60
$-1.35
Q4 24
$-0.04
$-0.76
Q3 24
$0.18
$-0.71
Q2 24
$0.98
$-0.88
Q1 24
$0.72
$-0.95

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EPC
EPC
OFIX
OFIX
Cash + ST InvestmentsLiquidity on hand
$82.0M
Total DebtLower is stronger
$1.5B
Stockholders' EquityBook value
$1.5B
$450.0M
Total Assets
$3.8B
$850.6M
Debt / EquityLower = less leverage
1.03×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EPC
EPC
OFIX
OFIX
Q4 25
$82.0M
Q3 25
$62.9M
Q2 25
$65.6M
Q1 25
$58.0M
Q4 24
$83.2M
Q3 24
$209.1M
$30.1M
Q2 24
$26.4M
Q1 24
$27.0M
Total Debt
EPC
EPC
OFIX
OFIX
Q4 25
$1.5B
Q3 25
$1.4B
$157.2M
Q2 25
$1.4B
$157.0M
Q1 25
$1.4B
$156.9M
Q4 24
$1.4B
$157.0M
Q3 24
$1.3B
$118.5M
Q2 24
$1.3B
$118.0M
Q1 24
$1.4B
$118.2M
Stockholders' Equity
EPC
EPC
OFIX
OFIX
Q4 25
$1.5B
$450.0M
Q3 25
$1.6B
$442.5M
Q2 25
$1.6B
$458.3M
Q1 25
$1.5B
$458.3M
Q4 24
$1.5B
$503.1M
Q3 24
$1.6B
$525.9M
Q2 24
$1.6B
$546.0M
Q1 24
$1.6B
$570.3M
Total Assets
EPC
EPC
OFIX
OFIX
Q4 25
$3.8B
$850.6M
Q3 25
$3.8B
$832.6M
Q2 25
$3.8B
$837.2M
Q1 25
$3.8B
$823.1M
Q4 24
$3.7B
$893.3M
Q3 24
$3.7B
$867.9M
Q2 24
$3.7B
$882.0M
Q1 24
$3.8B
$906.0M
Debt / Equity
EPC
EPC
OFIX
OFIX
Q4 25
1.03×
Q3 25
0.89×
0.36×
Q2 25
0.88×
0.34×
Q1 25
0.95×
0.34×
Q4 24
0.97×
0.31×
Q3 24
0.81×
0.23×
Q2 24
0.82×
0.22×
Q1 24
0.88×
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EPC
EPC
OFIX
OFIX
Operating Cash FlowLast quarter
$-125.9M
$27.7M
Free Cash FlowOCF − Capex
$-137.5M
$16.8M
FCF MarginFCF / Revenue
-32.5%
7.6%
Capex IntensityCapex / Revenue
2.7%
4.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$36.3M
$-1.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EPC
EPC
OFIX
OFIX
Q4 25
$-125.9M
$27.7M
Q3 25
$74.1M
$12.4M
Q2 25
$114.8M
$11.6M
Q1 25
$45.1M
$-18.4M
Q4 24
$-115.6M
$23.7M
Q3 24
$-388.3M
$11.7M
Q2 24
$101.2M
$9.0M
Q1 24
$129.0M
$-18.6M
Free Cash Flow
EPC
EPC
OFIX
OFIX
Q4 25
$-137.5M
$16.8M
Q3 25
$46.5M
$2.5M
Q2 25
$99.3M
$4.5M
Q1 25
$28.0M
$-25.1M
Q4 24
$-132.4M
$15.2M
Q3 24
$-414.2M
$6.3M
Q2 24
$88.6M
$-360.0K
Q1 24
$117.5M
$-29.1M
FCF Margin
EPC
EPC
OFIX
OFIX
Q4 25
-32.5%
7.6%
Q3 25
7.7%
1.2%
Q2 25
15.8%
2.2%
Q1 25
4.8%
-13.0%
Q4 24
-31.9%
7.0%
Q3 24
-80.0%
3.2%
Q2 24
13.7%
-0.2%
Q1 24
19.6%
-15.4%
Capex Intensity
EPC
EPC
OFIX
OFIX
Q4 25
2.7%
4.9%
Q3 25
4.6%
4.8%
Q2 25
2.5%
3.5%
Q1 25
2.9%
3.5%
Q4 24
4.0%
4.0%
Q3 24
5.0%
2.7%
Q2 24
1.9%
4.7%
Q1 24
1.9%
5.6%
Cash Conversion
EPC
EPC
OFIX
OFIX
Q4 25
Q3 25
Q2 25
3.95×
Q1 25
1.56×
Q4 24
Q3 24
-44.13×
Q2 24
2.07×
Q1 24
3.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EPC
EPC

Other$242.0M57%
Sunand Skin Care Segment$131.5M31%
Shavinggelsandcreams$32.3M8%
Wipes And Other Skin Care Products$17.0M4%

OFIX
OFIX

Spinal Implants Biologics And Enabling Technologies$113.6M52%
Bone Growth Therapies$68.3M31%
Other$22.7M10%
IT$5.9M3%
GB$3.5M2%
FR$3.5M2%
DE$2.3M1%

Related Comparisons